# Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

> **NCT06947967** · PHASE3 · RECRUITING · sponsor: **Chipscreen Biosciences, Ltd.** · enrollment: 224 (estimated)

## Conditions studied

- Lymphoma, T-Cell, Peripheral

## Interventions

- **DRUG:** CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)
- **DRUG:** Tucidinostat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06947967
- **Lead sponsor:** Chipscreen Biosciences, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-12
- **Primary completion:** 2032-12
- **Final completion:** 2032-12
- **Target enrollment:** 224 (ESTIMATED)
- **Last updated:** 2025-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06947967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06947967, "Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06947967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*